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SNP arrayMelanoma has a high tendency tometastasize to brain tissue. The understanding about themolecular alterations of
early-stage melanoma progression to brain metastasis (MBM) is very limited. Identifying MBM-speciﬁc genomic
and epigenomic alterations is a key initial step in understanding its aggressive nature and identifying speciﬁc
novel druggable targets. Here, we describe a multi-platform dataset generated with different stages of melanoma
progression to MBM. This data includes genome-wide DNA methylation (Illumina HM450K BeadChip), gene
expression (Affymetrix HuEx 1.0 ST array), single nucleotide polymorphisms (SNPs) and copy number variation
(CNV; Affymetrix SNP 6.0 array) analyses of melanocyte cells (MNCs), primary melanoma tumors (PRMs), lymph
node metastases (LNMs) and MBMs. The analysis of this data has been reported in our recently published study
(Marzese et al., 2014).
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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GSE44019.Experimental design, materials and methods
We selected and analyzed three melanoma-related tissue types
(PRMs, LNMs andMBMs) and normal melanocytes (MNCs) representing
themelanoma progression toMBM. Compared to other solid tumors, the
study of melanoma progression involves important challenges. First, the
conventionally accepted normal controls for melanoma are short-term
cultured MNC cells. Second, due to the small size of PRM and MBM le-
sions, tissue availability is usually very limited. Our study focused on
DNA methylation, which was analyzed for all the samples (n = 40;
GSE44661). To evaluate the potential transcriptional impact of DNA
methylation changes on MBM-development, RNA expression was also
assessed in metastatic melanomas and MNCs (n = 22; GSE44660). To
exclude the inﬂuence of SNPs or allele CNV on DNA methylation analy-
sis, genome-wide SNP analysis was performed onmetastatic melanomas
(n = 16; GSE44019).r the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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This study included three human MNCs isolated from normal skin
(Life Technologies, Carlsbad, CA), four parafﬁn-embedded archival
tissue (PEAT) PRMs obtained from AJCC Stage II melanoma patients,
seventeen LNMs (PEAT and cultured cells) obtained from AJCC Stage
III melanoma patients and sixteen MBMs (PEAT and cultured cells) ob-
tained from AJCC Stage IV melanoma patients. Importantly, LNMs were
classiﬁed based on disease-free survival (DFS) into good (n = 10;
DFSN5 yr) and poor (n = 7; DFSb2 yr) prognosis groups (Table 1).
Melanoma patients were included in the study under protocols ap-
proved by Providence Saint John's Health Center/JWCI joint institutional
review board and Western institutional review board and the Sydney
Local Health District, RPAH Zone, Human Ethics Review Committee. In-
formed consent was obtained from all subjects and the experiments
were performed according to the principles set out in the WMA Decla-
ration of Helsinki and the NIH Belmont Report. Tissue specimens were
coded according toHIPAA recommendations to ensure the conﬁdential-
ity of the patients.
DNA methylation proﬁling
DNA methylation assays were performed using Illumina
HumanMethylation450 (HM450K) BeadChip following the
manufacturer's protocol (Illumina, San Diego, CA). The chips were
scanned with Illumina iScan microarray scanner (Illumina), and theTable 1
Specimens included in the study.
Name Source PEAT/cells L
Melanocyte 1 MNC Cells N
Melanocyte 2 MNC Cells N
Melanocyte 3 MNC Cells N
Primary melanoma 1 PRM PEAT N
Primary melanoma 2 PRM PEAT N
Primary melanoma 3 PRM PEAT N
Primary melanoma 4 PRM PEAT N
Lymph node metastasis 1 LNM Cells G
Lymph node metastasis 2 LNM Cells G
Lymph node metastasis 3 LNM Cells G
Lymph node metastasis 4 LNM Cells P
Lymph node metastasis 5 LNM Cells G
Lymph node metastasis 6 LNM Cells G
Lymph node metastasis 7 LNM Cells G
Lymph node metastasis 8 LNM Cells P
Lymph node metastasis 9 LNM Cells P
Lymph node metastasis 10 LNM Cells G
Lymph node metastasis 11 LNM Cells G
Lymph node metastasis 12 LNM Cells G
Lymph node metastasis 13 LNM Cells G
Lymph node metastasis 14 LNM PEAT P
Lymph node metastasis 15 LNM PEAT P
Lymph node metastasis 16 LNM PEAT P
Lymph node metastasis 17 LNM PEAT P
Brain metastasis 1 MBM Cells N
Brain metastasis 2 MBM Cells N
Brain metastasis 3 MBM Cells N
Brain metastasis 4 MBM Cells N
Brain metastasis 5 MBM Cells N
Brain metastasis 6 MBM Cells N
Brain metastasis 7 MBM Cells N
Brain metastasis 8 MBM Cells N
Brain metastasis 9 MBM PEAT N
Brain metastasis 10 MBM PEAT N
Brain metastasis 11 MBM PEAT N
Brain metastasis 12 MBM PEAT N
Brain metastasis 13 MBM PEAT N
Brain metastasis 14 MBM PEAT N
Brain metastasis 15 MBM PEAT N
Brain metastasis 16 MBM PEAT Ndata was extracted using the R package methylumi on Bioconductor.
The methylation levels were reported as a β-value [β= intensity of
the Methylated allele/(intensity of the Unmethylated allele + inten-
sity of the Methylated allele)], and calculated using the signal inten-
sity value for each CpG site.
Genome variation proﬁling
Genotyping of DNA from melanoma specimens was performed
using Affymetrix Genome-Wide Human SNP Array 6.0 by following
the manufacturer's recommendations (Affymetrix, Santa Clara, CA).
The genotype calls of each specimen were determined by the Birdseed
2.0 genotype calling algorithm included in the Affymetrix Genotyping
Console 4.0. Quality control (QC) of arrays was conducted using the
Contrast Quality Control (CQC) algorithm, with a minimal call rate of
N95%. Copy number (CN) analysiswas performed using regional GC cor-
rection and default software settings. CN segments were reported with
anHMMalgorithmusing the default CNmap in Genotyping Console 4.0
(Toronto DGV map).
Gene expression proﬁling
Total RNA was analyzed by GeneChip Human Exon ST Array 1.0
(HuEx 1.0) following the manufacturer's protocol (Affymetrix). Data
were analyzed in Expression Console 1.1 software (Affymetrix) usingNM prognostic HM450K SNP 6.0 HuEx 1.0
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algorithm (RMA) for background correction and normalization of data.
Basic analysis
As we described [1], DNA methylation data was ﬁltered to exclude
probes associated with SNPs, regions with commonly occurring CNV
and sex chromosomes. Additionally, after background correction,
probes with no signiﬁcant difference from the background noise
(P N 0.01) were called “failed” and excluded from downstream analy-
ses. Samples presenting ≥0.5% of failed probes were excluded from
the study. Candidate CpG sites with differential methylation among
study groups were validated as functional by seeking statistical differ-
ences in RNA expression. Top candidates were then selected for direct
assay veriﬁcation as we described [1].Discussion
In this Data in Brief article, we described in detail the contents of the
dataset associated with the study published by Marzese and colleagues
in the HumanMolecular Genetics journal in 2014 [1]. This multiplatform
analysis offers the opportunity of identifying genetic and epigenetic
alterations that can be used as potential theranostic biomarkers for
melanoma progression to MBM.
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